Saturday 17 October 2026
Export CSTL’s income statement to Excel — free account
Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
31.96
1.84
−5.44%
Follow CSTL
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00 | 0.00 |
Piotroski F-Score |
— | — | — | 4 | 1 | 2 | 5 | 7 | 3 |
Altman Z-Score |
— | — | 6.15 | 33.28 | 13.21 | 7.59 | 5.56 | 6.74 | 6.70 |
P/S ratio |
1.70 | 1.70 | 5.69 | 20.29 | 11.45 | 4.33 | 2.68 | 2.23 | 3.28 |
Altman Z″-Score (non-manufacturers) |
— | (6.93) | 7.12 | 24.00 | 11.93 | 10.19 | 7.63 | 9.07 | 6.15 |
P/FCF ratio |
0.00 | 0.00 | 48.54 | 248.40 | 0.00 | 0.00 | 0.00 | 20.25 | 39.74 |
Beneish M-Score |
— | — | (2.01) | (2.38) | 11.61 | (2.41) | (2.37) | (2.58) | (3.49) |
P/Operating CF |
95.59 | 95.59 | 65.66 | (2,956.01) | (387.49) | (98.92) | 31.67 | 30.38 | 41.87 |
P/B ratio |
0.00 | 0.00 | 3.47 | 3.06 | 2.62 | 1.49 | 1.50 | 1.62 | 2.39 |
Price to Tangible BV |
0.00 | 0.00 | 3.47 | 3.06 | 3.34 | 2.18 | 2.15 | 2.12 | 3.04 |
EV/Sales |
1.96 | 1.96 | 4.27 | 14.11 | 8.04 | 2.54 | 1.64 | 1.38 | 2.44 |
EV/EBITDA |
0.00 | 0.00 | 23.03 | 0.00 | 0.00 | 0.00 | 0.00 | 25.44 | 0.00 |
EV/Operating CF |
(16.06) | (16.06) | 31.55 | 89.58 | (39.83) | (8.36) | (63.99) | 7.05 | 13.03 |
EV/FCF |
(13.90) | (13.90) | 36.41 | 172.70 | (33.67) | (7.39) | (18.72) | 12.51 | 29.55 |
Quick Ratio |
1.12 | 2.46 | 7.42 | 20.24 | 13.94 | 7.81 | 5.90 | 6.97 | 4.99 |
Current Ratio |
1.28 | 2.69 | 7.63 | 20.58 | 14.21 | 8.09 | 6.20 | 7.29 | 5.26 |
Net Debt/EBITDA |
(1.78) | (6.79) | (7.67) | 78.35 | 8.77 | 3.85 | 3.98 | (15.73) | 46.20 |
Debt/Assets |
0.00% | 109.35% | 20.98% | 0.00% | 1.75% | 2.98% | 0.00% | 1.95% | 1.79% |
Debt/Equity |
(1.27) | (0.43) | 0.30 | 0.00 | 0.02 | 0.03 | 0.00 | 0.02 | 0.02 |
Asset Turnover |
0.85 | 2.03 | 0.73 | 0.22 | 0.21 | 0.30 | 0.49 | 0.67 | 0.62 |
Operating CF/Net income |
0.80 | 1.21 | 2.35 | (0.96) | 0.61 | 0.62 | 0.10 | 3.56 | (2.66) |
Capex/Depreciation |
0.00 | (0.31) | (0.41) | (3.62) | (1.02) | (0.59) | (1.99) | (3.04) | (0.98) |
Interest Coverage |
(13.01) | (1.69) | 1.60 | (2.48) | (40,079.00) | (4,285.59) | (6,179.73) | 15.03 | (497.79) |
| 28.65% | 19.02% | 20.95% | (4.11%) | (7.56%) | (16.56%) | (14.54%) | 4.31% | (5.21%) | |
| (95.00%) | (90.72%) | 4.21% | (3.68%) | (6.94%) | (14.76%) | (12.76%) | 3.71% | (4.35%) | |
ROIC |
0.00% | 0.00% | 40.21% | (70.02%) | (27.78%) | (29.60%) | (28.67%) | 3.13% | (14.72%) |
Return on Tangible Assets |
(521.83%) | (78.67%) | 2.89% | (2.47%) | (9.25%) | (24.82%) | (21.02%) | 5.04% | (6.20%) |
Average Days of Receivables |
123.46 | 193.67 | 103.09 | 74.34 | 67.05 | 62.53 | 63.61 | 56.30 | 46.00 |
Research and Development Expense of Revenue |
32.21% | 21.30% | 14.24% | 21.16% | 31.51% | 32.77% | 24.40% | 15.67% | 15.06% |
Selling, General and Administrative Expense of Revenue |
110.37% | 72.29% | 57.54% | 76.83% | 92.19% | 104.35% | 81.97% | 60.24% | 66.62% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.28 | 0.26 | 0.20 | 0.17 |
Share Based Compensation of Revenue |
0.00% | 1.29% | 2.41% | 13.26% | 23.11% | 26.50% | 23.30% | 15.15% | 13.33% |
Graham Net Nets |
(1.19) | (1.19) | 0.28 | 0.32 | 0.28 | 0.41 | 0.40 | 0.38 | 0.22 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.49 | 0.00 |
Earnings Yield |
(24.42%) | (24.42%) | (3.52%) | (0.76%) | (2.89%) | (11.33%) | (9.84%) | 2.44% | (2.16%) |
Free Cash Flow Yield |
(8.33%) | (8.33%) | 2.06% | 0.40% | (2.08%) | (7.93%) | (3.27%) | 4.94% | 2.52% |
Revenue per Share |
0.83 | 11.95 | 6.04 | 3.31 | 3.74 | 5.26 | 8.20 | 11.96 | 11.88 |
Operating CF per Share |
(0.73) | (6.45) | 0.82 | 0.52 | (0.76) | (1.60) | (0.21) | 2.34 | 2.22 |
Capex per Share |
0.00 | (0.15) | (0.11) | (0.25) | (0.14) | (0.21) | (0.51) | (1.02) | (1.24) |
Free Cash Flow per Share |
(0.73) | (6.60) | 0.71 | 0.27 | (0.89) | (1.81) | (0.72) | 1.32 | 0.98 |
Cash per Share |
0.07 | 2.35 | 11.52 | 21.65 | 13.11 | 9.93 | 9.07 | 10.55 | 10.33 |
Shareholders Equity per Share |
(0.95) | (29.68) | 9.92 | 21.96 | 16.38 | 15.32 | 14.60 | 16.41 | 16.24 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.95) | (29.68) | 9.92 | 21.96 | 16.38 | 15.32 | 14.60 | 16.41 | 16.24 |
Free Cash Flow |
(12.23) | (12.57) | 6.08 | 5.12 | (22.46) | (47.09) | (19.23) | 36.56 | 28.37 |
Working Capital |
1.46 | 11.39 | 101.39 | 408.72 | 328.86 | 256.16 | 247.97 | 310.76 | 292.42 |
Capital Expenditures |
(0.49) | (0.28) | (0.94) | (4.75) | (3.47) | (5.44) | (13.61) | (28.31) | (35.98) |
Net Current Asset Value |
(18.91) | (60.84) | 82.05 | 405.96 | 302.91 | 244.11 | 233.56 | 284.75 | 253.41 |
EV/EBIT |
0.00 | 0.00 | 30.20 | 0.00 | 0.00 | 0.00 | 0.00 | 52.76 | 0.00 |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.08 | 0.04 | 0.04 | 0.06 | 0.09 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 40.26 | 0.00 | 0.00 | 0.00 | 0.00 | 85.38 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.21 | 0.58 | 1.11 | 0.18 | 0.36 | 0.64 | 0.27 | 0.18 | 0.38 |
Cash ROIC |
(220.68%) | 45.57% | 2.91% | 0.62% | (3.00%) | (7.02%) | (3.03%) | 4.81% | 3.63% |
Accounts Receivable Turnover |
1.64 | 2.72 | 3.88 | 4.57 | 6.26 | 6.72 | 7.12 | 7.42 | 7.28 |
Accounts Payable Turnover |
3.93 | 4.13 | 4.41 | 4.89 | 6.81 | 8.80 | 6.00 | 7.01 | 5.55 |
Inventory Turnover |
8.50 | 8.93 | 6.90 | 5.61 | 7.47 | 10.67 | 7.55 | 7.49 | 7.73 |
Average Days of Payables |
80.81 | 99.98 | 93.12 | 79.07 | 58.73 | 53.95 | 83.32 | 41.84 | 96.15 |
Days of Inventory on Hand |
22.04 | 60.78 | 61.77 | 83.55 | 46.62 | 45.38 | 64.44 | 49.32 | 52.69 |
Average Receivables |
8.37 | 8.37 | 13.37 | 13.70 | 15.02 | 20.38 | 30.89 | 44.76 | 47.30 |
Average Payables |
1.28 | 1.28 | 1.66 | 1.98 | 2.32 | 3.64 | 7.50 | 8.58 | 12.81 |
Average Inventory |
0.59 | 0.59 | 1.06 | 1.73 | 2.12 | 3.00 | 5.96 | 8.04 | 9.19 |
Average Assets |
16.11 | 11.20 | 71.08 | 279.54 | 450.95 | 454.95 | 450.33 | 492.29 | 554.90 |
Average Common Equity |
(53.44) | (53.44) | 14.27 | 250.40 | 413.72 | 405.45 | 395.21 | 423.55 | 463.35 |
Columns are period end dates